The Effect of Topical Avastin in the Success Rate of Dacryocystorhinostomy

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Ophthalmology, School of Medicine AND Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Resident, Department of Anesthesiology and Critical Care, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Ophthalmology, School of Medicine AND Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Resident, Department of Ophthalmology, School of Medicine AND Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Many factors are involved in the failure rate of dacryocystorhinostomy (DCR) surgery as the standard treatment of nasolacrimal duct obstruction. There is however, a lot of evidence that bevacizumab (Avastin) with less side effects, has the same anti-fibrosis effects. In this study we evaluated the effect of this drug on the failure rate of DCR.Methods: 60 candidates for DCR were divided to two groups each one containing 30 patients. These 2 groups were matched by age and sex. We used Avastin eye-drops (5 mg/ml) every 6 hours in one group for 2 weeks in addition to other post-op routine treatments. The patients were evaluated for failure of DCR 2 weeks and 3 months after surgery.Findings: In the Avasin group no patient showed surgery failure. In the other group, 1 patient in 2 week and 2 patients in 3 months follow-up showed failure. However this difference between 2 groups was not statistically significant and maybe due to small sample size. (P = 0.327, Fisher exact test).Conclusion: Avastin eye drop may lower the failure rate of DCR. This subject needs to be more evaluated in further studies.

Keywords

References

  1. Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, Re M. The outcomes of endoscopic dacryocystorhinostomy in children: A systematic review. Int J Pediatr Otorhinolaryngol 2015; 79(7): 947-52.
  2. Ali MJ, Psaltis AJ, Wormald PJ. Dacryocystorhinostomy ostium: parameters to evaluate and DCR ostium scoring. Clin Ophthalmol 2014; 8: 2491-9.
  3. Savino G, Battendieri R, Traina S, Corbo G, D'Amico G, Gari M, et al. External vs. endonasal dacryocystorhinostomy: has the current view changed? Acta Otorhinolaryngol Ital 2014; 34(1): 29-35.
  4. Bukhari AA. Meta-analysis of the effect of posterior mucosal flap anastomosis in primary external dacryocystorhinostomy. Clin Ophthalmol 2013; 7: 2281-5.
  5. Lee J, Yang SW, Lee H, Chang M, Park M, Baek S. Association of rhinostomy shape and surgical outcome after endoscopic endonasal dacryocystorhinostomy. Graefes Arch Clin Exp Ophthalmol 2015; 253(9): 1601-7.
  6. Huang J, Malek J, Chin D, Snidvongs K, Wilcsek G, Tumuluri K, et al. Systematic review and meta-analysis on outcomes for endoscopic versus external dacryocystorhinostomy. Orbit 2014; 33(2): 81-90.
  7. Rahman A, Channa S, Niazi JH, Memon MS. Dacryocystorhinostomy without intubation with intraoperative mitomycin-C. J Coll Physicians Surg Pak 2006; 16(7): 476-8.
  8. Naik SM, Appaji MK, Ravishankara S, Mushannavar AS, Naik SS. Endonasal DCR with Silicon Tube Stents: A Better Management for Acute Lacrimal Abscesses. Indian J Otolaryngol Head Neck Surg 2013; 65(Suppl 2): 343-9.
  9. Kumar V, Ali MJ, Ramachandran C. Effect of mitomycin-C on contraction and migration of human nasal mucosa fibroblasts: implications in dacryocystorhinostomy. Br J Ophthalmol 2015; 99(9): 1295-300.
  10. Xue K, Mellington FE, Norris JH. Meta-analysis of the adjunctive use of mitomycin C in primary and revision, external and endonasal dacryocystorhinostomy. Orbit 2014; 33(4): 239-44.
  11. Mearza AA, Aslanides IM. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf 2007; 6(1): 27-32.
  12. Cheng G, Xiang H, Yang G, Ma J, Zhao J. Direct Effects of Bevacizumab on Rat Conjunctival Fibroblast. Cell Biochem Biophys 2015; 73(1): 45-50.
  13. Uyeturk U, Gucuk A, Firat T, Kemahli E, Kukner A, Ozyalvacli ME. Effect of mitomycin, bevacizumab, and 5-Fluorouracil to inhibit urethral fibrosis in a rabbit model. J Endourol 2014; 28(11): 1363-7.
  14. Ozkan U, Osun A, Samancioglu A, Ercan S, Firat U, Kemaloglu S. The effect of bevacizumab and 5-Fluorouracil combination on epidural fibrosis in a rat laminectomy model. Eur Rev Med Pharmacol Sci 2014; 18(1): 95-100.
  15. Vandewalle E, Abegao PL, van Bergen T, Spielberg L, Fieuws S, Moons L, et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol 2014; 98(1): 73-8.
  16. Martin GE, Rivera ZM, Perucho MS, Toledano FN. Comparison study on the efficacy and safety of bevacizumab versus mitomycin C as adjuvants in trabeculectomy. Arch Soc Esp Oftalmol 2015; 90(2): 63-8. [In Spanish].
  17. Lee KS, Ko DA, Kim ES, Kim MJ, Tchah H, Kim JY. Bevacizumab and rapamycin can decrease corneal opacity and apoptotic keratocyte number following photorefractive keratectomy. Invest Ophthalmol Vis Sci 2012; 53(12): 7645-53.
  18. Park YM, Kim CD, Lee JS. Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium. Korean J Physiol Pharmacol 2015; 19(4): 357-63.
  19. Nava-Castaneda A, Ulloa-Orozco I, Garnica-Hayashi L, Hernandez-Org, Jimenez-Martinez MC, Garfias Y. Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. J Ocul Pharmacol Ther 2015; 31(2): 106-13.
  20. Makris G, Kantzioura A, Beredima M, Karampola M, Emmanouilides C. Feasibility of rapid infusion of the initial dose of bevacizumab in patients with cancer. J BUON 2015; 20(3): 923-7.
  21. Ozdemir O, Altintas O, Altintas L, Ozkan B, Akdag C, Yuksel N. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. Arq Bras Oftalmol 2014; 77(4): 209-13.
Journal of Isfahan Medical School
Volume 34, Issue 387 - Serial Number 387
May and June 2016
Pages 718-723

Files

History

  • Receive Date: 29 January 2016
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics